Key result
Contradictory REDUCE-AMI and ABYSS trials do not change beta-blocker guidelines for secondary MI prevention.
Why the study?
Most trials showing beta-blocker benefits after myocardial infarction predated modern biomarkers and acute/long-term therapy, necessitating new evidence in patients with preserved left ventricular systolic function.
Do beta-blockers improve mortality and morbidity in patients after myocardial infarction with preserved left ventricular systolic function?
Do beta-blockers improve mortality and morbidity in patients after myocardial infarction with preserved left ventricular systolic function?
Recent trials (REDUCE-AMI and ABYSS) do not currently justify changing the European guidelines for beta-blocker use in the secondary prevention of myocardial infarction.
Answers are grounded in this paper and cite their sources.
Contradictory REDUCE-AMI/ABYSS results do not warrant guideline revision; leaves beta-blocker role post-MI with preserved LVEF unresolved.
Betabloktory zlepuj dlouhodobou prognzu pacient po prodlanm infarktu myokardu. Jejich pnos je nepochybn u pacient, kte maj znmky srden insuficience i dysfunkci lev komory srden. Pozitivn inky vak podle souasnch evropskch guidelines pevauj i u ostatnch pacient. Vtina studi, kter prokzaly snen mortality i morbidity, byla provedena u pacient s velkmi infarkty v dob, kdy nebyla k dispozici diagnostika pomoc modernch biomarker a inn akutn i dlouhodob lba. Jsou proto zapoteb nov klinick studie zkoumajc pnos betabloktor u pacient se zachovanou systolickou funkc lev komory, kte jsou leni modern farmakoterapi. Ponkud rozporn vsledky nedvno publikovanch studi REDUCE-AMI a ABYSS zatm nejsou dvodem k prav souasnch doporuen pro sekundrn prevenci infarktu myokardu.
No takes yet. Share an insight, caveat, or question.
Petr Janský (2025) conducted a review in Myocardial infarction. Beta-blockers vs. No beta-blockers / Treatment interruption was evaluated. Recent contradictory results from the REDUCE-AMI and ABYSS trials do not currently warrant a change in guidelines for beta-blocker use in the secondary prevention of myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: